01 - 20 - 2017
Herpes : a vaccine candidate against the HSV-2 virus
HSV-1 and HSV-2 are two viruses responsible for both forms of herpes. HSV-2 is sexually transmitted and promotes HIV infection. 11% of the world’s 15-49 year-olds are infected, that is around 400 million people and there is no vaccine.
A candidate vaccine against HSV-2 appears to be very effective in preventing infection in guinea pigs and macaques. It is candidate to enter clinical trials in humans in order to prevent infections by the virus.
01 - 19 - 2017
Post-Traumatic Stress Disorder in Women
Women are twice as likely as men to develop post-traumatic stress disorder (PTSD) after a traumatic experience. This difference appears during the phases of their cycle when oestrogen levels are low.
Studies in women and mouse models have shown that oestrogen levels influence the expression of the HDAC4 gene involved in long-term memory formation and behaviour, which could explain the sensitivity of women to PTSD. Research is ongoing to find out if oestrogen could help prevent PTSD in women.
01 - 18 - 2017
The adaptation of primates to the HIV-1 virus
The protein Schlafen11, found in primates, has an anti-HIV-1 activity that is unfortunately quite low in humans. Researchers have shown in vitro that in other primates such as marmosets or chimpanzees, this anti-HIV-1 effect was much more potent. But these species cousins to humans are resistant to AIDS.
Studies are on-going to understand how non-human primates can be resistant to HIV-1 and other viral infections and what are the evolving mechanisms that drive this competition between viruses and their host species. This fundamental research improves our understanding of the susceptibility of species to viruses and can be a stepping point for medical advances.
01 - 17 - 2017
Propranolol and sarcoma : from research to treatment
An antihypertensive drug used in medicine for decades, propranolol, has just obtained the European approval for its use against certain soft tissue cancers very resistant to treatments: sarcomas.
This efficacy of this product was demonstrated on cell and animal models in 2013. Subsequent clinical trials have confirmed the efficacy in patients and resulted in the approval.
No front page content has been created yet.